The consensus remains at US$14.50 despite weaker earnings fo...

The consensus remains at US$14.50 despite weaker earnings forecast, suggesting a belief in a minimal long-term impact to valuation. Yet, the rise in anticipated losses next year and reduced revenue predictions might raise investor concerns about Theravance Biopharma.